摘要:
The present invention relates to novel therapies that utilize HSP70 fusion proteins for the treatment of disorders or conditions regulated by HSP70.
摘要:
The present invention relates to novel therapies that utilize HSP70 fusion proteins for the treatment of disorders or conditions regulated by HSP70.
摘要:
The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.
摘要:
The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.
摘要:
The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.
摘要:
The present invention relates to novel therapies that utilize stabilized exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of degradation resistant formulations of HSP70. Furthermore, the present invention is directed to methods comprising the administration of stabilized exogenous HSP70 for use in the treatment of HSP70 related disorders or conditions, for example, for increased endurance or alleviating fatigue syndrome.
摘要:
The present invention relates to novel therapies that utilize stabilized exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of degradation resistant formulations of HSP70. Furthermore, the present invention is directed to methods comprising the administration of stabilized exogenous HSP70 for use in the treatment of HSP70 related disorders or conditions, for example, for increased endurance or alleviating fatigue syndrome
摘要:
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
摘要:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
摘要:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.